Latest news
New study from Maverex on the risk of stroke and myocardial infarction in systemic lupus erythematosus patients
Posted on September 21, 2020Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis developed with our partners at AstraZeneca, is a systematic review of the risk of stroke and myocardial infarction (MI) in adult patients with systemic lupus erythematosus (SLE), a chronic autoimmune disorder associated with increased comorbidities. Epidemiological studies have suggested that patients …
Read more
New Maverex cost-consequence analysis of triple-chamber-bag parenteral nutrition in preterm neonates
Posted on September 21, 2020In Cost-Consequences Analysis of Increased Utilization of Triple-Chamber-Bag Parenteral Nutrition in Preterm Neonates in Seven European Countries, alongside our partners at Baxter Healthcare, we assessed national-level impacts of a 10-percentage point increase in use of industry-prepared three-chamber bags (3CBs) on clinical outcomes, healthcare resources, and hospital budgets across seven countries: Belgium, France, Germany, Italy, …
Read more
We’re going to Virtual PPMA 2020
Posted on September 19, 2020After a truly exciting time in Amsterdam last year for World Pharma Pricing, Evidence and Market Access Congress, the Maverex team is looking forward to this year’s PPMA virtual congress. Although this year’s congress will be virtual, we’ve lined up plenty of interesting talks and we’re still looking forward to networking with others who are …
Read more
Maverex Posters at ISPOR Europe 2020
Posted on September 4, 2020ISPOR Europe is one of our favourite fixtures on the Maverex calendar. Although this year will be slightly different and we’re disappointed to not be flying out to Milan, we’re still looking forward to logging on to the virtual conference from the comfort of the Maverex office and our own homes. This year, ISPOR …
Read more
Maverex celebrates its women-owned business status
Posted on June 9, 2020At the end of May 2020, Maverex was formally recognised by WEConnect International, a not-for-profit organisation working to connect women-owned and controlled businesses globally. Maverex was awarded with a certification for Women’s Business Enterprise; acknowledging Maverex not only as a women-owned company, but as also wanting to do business with others who are committed …
Read more
New publication from Maverex on COPD
Posted on December 9, 2019New publication from Maverex – Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review – in Respiratory Research We are delighted to announce that our latest publication, a systematic review of the safety and efficacy of single-inhaler triple therapies for chronic obstructive pulmonary disorder (COPD), is now available at Respiratory …
Read more
Maverex launch innovative digital tools at ISPOR 2019
Posted on November 2, 2019Maverex launch innovative digital tools at ISPOR 2019 – Interactive Model Builder and Payer Value Platform With the theme of ISPOR Europe 2019 being ‘Digital Transformation of Healthcare’, it’s the perfect time to launch our exciting new digital tools and we can’t wait to share them with you. Following on from the success …
Read more
Maverex posters at ISPOR Copenhagen 2019
Posted on October 4, 2019Maverex posters at ISPOR Copenhagen 2019 It’s that time of the year again, and the Maverex team is delighted to be attending ISPOR Europe in Copenhagen! As well as enjoying the beautiful city, we are keen to be there for presentations and discussions on the latest in determining value in healthcare and to catch …
Read more
Latest Maverex publication – Transparency in Decision Modelling
Posted on July 25, 2019Latest Maverex publication – Transparency in Decision Modelling Read our latest manuscript recently published in PharmacoEconomics – “Transparency in Decision Modelling: What, Why, Who and How?” We are pleased to share details of our most recent publication, which Nina, Antony and Sue have been involved in developing, discussing the opportunities and potential risks …
Read more
2019 World Pharma Pricing and Market Access congress
Posted on March 14, 20192019 World Pharma Pricing and Market Access congress Maverex are excited to announce that we will be attending the 2019 World Pharma Pricing and Market Access congress next week. Held at the Beurs van Berlage Conference Centre, Amsterdam, PPMA is Europe’s leading pricing, access and evidence congress. Our team will be available throughout the …
Read more